INOVIO Pharmaceuticals reports promising Phase I results for its DMAbs technology, showing 100% of subjects maintained relevant antibody levels with no serious adverse events.
Pfizer has initiated a Phase 3 clinical trial to assess ibuzatrelvir, a new oral antiviral drug, for treating non-hospitalized, high-risk COVID-19 patients.
Mayo Clinic Arizona found removing _C. difficile_ from gastrointestinal pathogen panels reduced unnecessary treatments and improved diagnostic stewardship.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.